London-based Tiziana Life Sciences Ltd is a pioneering biotech firm that specializes in the development and discovery of molecules to tackle diseases afflicting human oncology and immunology. Its flagship product in the latter category is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody that has the potential to treat a range of debilitating illnesses such as Crohn's, ulcerative colitis, psoriasis, multiple sclerosis, and rheumatoid arthritis. In addition to Foralumab, the company is also developing Milciclib (TZLS-201), a small-molecule inhibitor that can potentially control numerous cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases responsible for cell growth and cancer progression. Notably, Tiziana Life Sciences is also working on anti-Interleukin 6 receptor (IL6R) mAbs (TZLS-501) that use fully human monoclonal antibodies to treat IL6-induced inflammation and COVID-19 patients. Founded in 1998, Tiziana Life Sciences operates out of London, the UK.
Tiziana Life Sciences plc's ticker is TLSA
The company's shares trade on the NASDAQ stock exchange
They are based in London, England
There are 1-10 employees working at Tiziana Life Sciences plc
It is https://www.tizianalifesciences.com/
Tiziana Life Sciences plc is in the Healthcare sector
Tiziana Life Sciences plc is in the Biotechnology industry
The following five companies are Tiziana Life Sciences plc's industry peers: